Secondary Logo

Journal Logo

ASAIO CARDIAC ABSTRACT

NEW ANTICOAGULANT MONITORING FOR ARTIFICIAL ORGAN

Iwahashi, H1; Kimura, M1; Iwahashi, M2; Zaitsu, T1; Tashiro, T1; Morita, T3

Author Information
  • Free

Background: Warfarin therapy is widely used for various artificial organs. We measured the prothrombin level using J prothrombin activator, carinactivase-1 (CA-1) as a new monitoring system. Methods: 971 patients were examined. They were divided into 2 groups as follows: Croup V consisted of 813 patients in the mechanical valve replacement group. Croup C, 157 comprised implanted synthetic graft group. Group V divided control group (group VC; 98 patients) and treated with warfarin (group VW; 715 patients). And group C divided control group (group GC; 31 patients) and treated with warfarin group (group GW; 126 patients). All patients underwent both the CA-1 test PT-INR and TT. Results: Group V: the mean values of the CA-1 test was 112.8523.8 Kg/ml in group VC and 65.2±25.4μg/ml in group VW (p<0.05). The PTINR was 1.0±0.1 in group VC and 1.8±0.4 in group VW (p<0.05). The TT was 29.1±18.7% in Croup VC and 111.7±33.3% in group VW (p<0.05). In group VW, the CA-1 test correlated with the PTINR (R=-0.61, p<0.05), and the Thrombo test scores (R = 0.57, p<0.05) Group G: the mean value showed 100.3±22.4μg/ml in group CC. The mean value was 85.9±40.9μg/ml in group CW, and the findings of the CA-1 test correlated with the PT-INK (R = 0.53, p<0.0001) and the TT (R = 0.55, p<0.0001) findings. Conclusion: On the basis of these preliminary data, we recommend that the prothrombin level he considered to warfarin therapy. In addition, CA-1 test is quantitative analysis and required only 10μl of diluted plasma. Each examination took only about 30 minutes. This test will he used the artificial organ monitoring.

Copyright © 2004 by the American Society for Artificial Internal Organs